Alzheimer's Disease & Dementia Overview
Alzheimer's Disease & Dementia Overview
Dementia is the name for a decline in memory and thinking that has begun to take away the ability to manage everyday life. Alzheimer's disease is the commonest cause of it, but it is not the only one, and the difference matters because several of the others are treatable. This guide follows the order patients actually need: what the first change looks like and why it is not always memory, which causes have to be ruled out before any label is given, what biomarkers can and cannot now tell us, and which parts of treatment change daily life rather than a score.
-
48 hours
written opinion once complete records arrive
-
One team
neurology, neuropsychology, rehabilitation and nursing planning together
-
Biomarkers
amyloid PET and cerebrospinal fluid testing alongside 3.0T MRI
-
124+
countries and regions our international patients come from
What dementia is — and what Alzheimer's is
Dementia is a syndrome: an acquired decline in memory, thinking or judgement severe enough to take away the ability to manage everyday life. Alzheimer's disease is the commonest cause of that syndrome. Keeping the two apart is not pedantry — it is the whole point of an assessment, because the list of other causes includes several that can be treated, and one or two that can be reversed.
Alzheimer's itself is defined by two protein changes. Outside the cell, fragments of a protein called amyloid accumulate into plaques. Inside the cell, a protein called tau, which normally stabilises the internal skeleton of the neuron, becomes chemically altered and clumps into tangles. These changes begin years — in most estimates more than a decade — before anything is noticeable, and they spread through the brain in a broadly predictable order: the regions that lay down new memories first, then language and visuospatial regions, then the regions that support judgement and behaviour. That order is why the symptom that appears first tells you something about what is happening.
Three things follow from this, and the guide keeps returning to them. First, decline is the entry criterion, not the diagnosis: the question is what is causing it, and the answer changes what is done. Second, biology precedes symptoms by years, which is why someone can carry Alzheimer's pathology and think perfectly well — and why a positive biomarker result on its own is not a diagnosis of dementia. Third, the everyday function is the measure that matters: whether the person can still manage money, medicines, transport and a meal is a better guide to what needs doing than any single score.
What this is not: it is not a normal part of ageing, it is not caused by aluminium or by a single food, and it is not something a person can prevent by trying harder. Forgetfulness that is occasional and self-corrected is ordinary. Decline that is progressive, that others have noticed, and that has begun to cost independence is not, and the symptoms page sets out where that line sits.
The forms it takes, and what each one starts with
Alzheimer's is one disease with more than one presentation, and the dementias around it start in different places. Naming the presentation is practical: it decides which scan is ordered, which biomarkers are worth measuring, and which of the treatable alternatives has to be excluded first.
| Presentation | What is noticed first | What it means for the assessment |
|---|---|---|
| Amnestic Alzheimer's | Newly learned information not retained; the same question asked again; reliance on notes or on another person; dates and appointments lost | The typical presentation and the most common one. Structural MRI looks for medial temporal atrophy, and amyloid and tau testing is most often informative here |
| Language presentation | Word-finding failure and hesitant, effortful speech; sentences that lose their shape; comprehension and behaviour relatively preserved at first | Often called the logopenic variant. It is an Alzheimer's phenotype, but it is confused with frontotemporal dementia, and the distinction changes both prognosis and management |
| Visuospatial presentation | Difficulty judging distance, reading, dressing, recognising objects or faces; getting lost in familiar places; memory comparatively preserved early | Often called posterior cortical atrophy. It is frequently seen first by an optician, and the delay between that and a neurological opinion can be years |
| Frontotemporal dementia | Change in behaviour, judgement, empathy and disinhibition, or a progressive loss of words with preserved memory for events | A different disease from Alzheimer's, with a different pathology and different management. It often begins earlier, and behaviour — not memory — is the presenting problem |
| Lewy body dementia | Fluctuating attention, detailed visual hallucinations, parkinsonism, acting out dreams, and severe sensitivity to antipsychotic medicines | The distinguishing features are the fluctuation and the hallucinations. The sensitivity to antipsychotics is a safety issue, not a detail, and it belongs in the letter the family carries |
| Vascular cognitive impairment | Slowing of thinking and planning, often with a stepwise course and with gait and mood changes; imaging shows the vascular burden | Prevention becomes the treatment: blood pressure, lipids, diabetes, smoking and antithrombotic decisions all move the trajectory. The causes page sets out what is established |
| Normal pressure hydrocephalus | A gait that becomes magnetic and wide-based, urgency or incontinence of urine, and slowed thinking — the three together | The one on this list that can improve substantially after treatment. It is missed because the gait is attributed to age and the bladder to something else |
| Mixed disease | A picture that does not fit one column, most often Alzheimer's pathology alongside vascular burden | Common, particularly in later life, and the reason a single label often understates what is actually going on |
Each of these is a different starting point rather than a different disease in every case, and the reason to name them is what changes next: a person with a visuospatial presentation needs the posterior regions looked at specifically, a person with fluctuations needs Lewy body disease considered before any antipsychotic is prescribed, and a person with a gait change needs the question of hydrocephalus answered. The treatment page sets out what each of those leads to.
How it is staged: the biology and the life
Dementia is described on two scales at once, and they are not the same scale. One is clinical and biological: where the disease is in the brain and how far it has spread. The other is functional: what the person can still do, and what the people around them are carrying. Both are needed, because a person can look well in a consultation and be losing independence at home, and the second of those is what decides what gets arranged.
| Axis | What is recorded | Why it is recorded |
|---|---|---|
| Stage of the syndrome | Whether there is no measurable impairment, measurable impairment with preserved independence, or mild, moderate or severe dementia | The stage decides which medicines are appropriate, whether antibody treatment is even discussable, and how quickly the plan has to be made |
| Phenotype | Which domain led: memory, language, visuospatial function or behaviour | The leading domain points to the underlying pathology, and therefore to which biomarker is worth measuring |
| Biomarker status | Amyloid status, from PET or from cerebrospinal fluid; tau status; and the burden of neurodegeneration on imaging | It confirms the biology in life rather than at autopsy, and it is the entry criterion for antibody treatment |
| Instrumental activities | Managing money and medicines, using transport and the telephone, cooking, shopping, keeping appointments | These are lost first and they are what independence actually consists of. Their loss is the threshold at which a syndrome becomes dementia |
| Basic activities | Bathing, dressing, toileting, continence, transferring and feeding | These are lost later, and their loss is what determines the hours of care that are needed and therefore what has to be arranged |
| Behaviour and mood | Agitation, apathy, sleep, hallucinations, resistance to care, and the caregiver's own state | Behaviour, not memory, is what drives admissions and what exhausts families, and it is the part most often left unaddressed |
| Safety and decisions | Driving, wandering, the kitchen, money, and whether the legal arrangements exist and were made in time | These carry the largest practical consequence in the whole illness, and all of them have to be settled while capacity still exists |
Recording both axes is what prevents the two common errors: treating someone as further along than they are because one score has fallen, and missing real decline because the person still converses well.
How the assessment is assembled
No single test diagnoses dementia, and no single test rules it out. An assessment is a set of questions, each answered by a different piece of evidence, and the order matters: the cheap and reversible answers come first, and the expensive and confirmatory ones come after they have been excluded.
| Element | The question it answers | What it does not do |
|---|---|---|
| History with a person who knows them | What changed, when it started, how fast it moved, and whether it fluctuates | It cannot be replaced by a scan, and it is the single most informative part of the assessment |
| Cognitive and functional testing | Which domains are affected, how severely, and whether independence has been lost | A score alone does not diagnose a cause, and a normal score does not exclude early disease |
| Blood tests and medication review | Whether a deficiency, a hormonal cause, an infection or a drug burden is responsible or contributing | Normal blood tests do not exclude Alzheimer's; they exclude the things that imitate it |
| Structural MRI | What the pattern of atrophy is, how much vascular burden there is, and whether there is a structural or reversible cause | It supports a diagnosis; it does not on its own prove Alzheimer's pathology |
| Amyloid PET or cerebrospinal fluid testing | Whether Alzheimer's biology is present, in someone whose presentation makes that the question | A positive result in a person with normal cognition is not dementia, and the test is only worth doing when the result will change management |
| Blood phosphorylated tau | The same question, increasingly answerable from a blood sample, with fewer people needing lumbar puncture or PET | It is interpreted with the phenotype and the examination, not as a screening test in someone with no symptoms |
| Sleep, mood, hearing and pain assessment | Whether something treatable is currently making the cognition worse than it needs to be | These are usually the largest reversible component, and they are usually the last thing considered |
| The second assessment, months later | Whether this is progressive, which is the defining feature rather than a detail | A single visit cannot establish trajectory, and trajectory is what separates decline from a bad year |
The exclusion work at the top of that table is not a formality and it is not defensive medicine. It is the part that finds the conditions with a different treatment, and the diagnosis page sets out each one and what happens when it is found.
Why patients travel to China for a dementia assessment
The reason is usually not that the assessment cannot be done at home. It is that the pieces of it are spread across appointments that are months apart, and that the reversible causes — the part worth doing first — are the part most often left undone. What an international assessment adds is compression and sequence: the history, the cognitive testing, the blood work and medication review, the imaging and, where it will change management, the biomarker testing, arranged in one pathway with one team reading them together.
Neurology and neuropsychology work within a service organised to national standardised stroke centre requirements, holding national stroke centre construction unit status and national good clinical practice accreditation; rehabilitation and nursing are in the same pathway rather than in a separate referral. The investigations are available on site — 3.0T MRI, dual-source CT, PET-CT, 3D DSA and long-term video EEG — which is what allows amyloid PET, perfusion imaging and structural imaging to be read against each other rather than in separate letters written a year apart.
Two practical points follow from doing it this way. The written opinion is returned once complete records arrive, and it states what the records support, which reversible causes have and have not been excluded, and whether travelling would add anything to the care already being received — before any payment is discussed. And because dementia is followed over years rather than treated in a week, the useful outcome of a visit is not a procedure but a plan that a local team can execute: what is being measured, at what interval, and what should trigger a change.